Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
s# .. exactly.
I would think the idea (ref home out-patient use) is that its the earlier (than otherwise) release from hospital of Int'f treated in-patients, who can continue that treatment at home ... vis-a-viv and extension of initial hospital treatment.
Very interesting B4Golf. Like most things, timing is key. SNG, in addition to a (hopefully) successful endgame in terms of data and authorisations, will rise up the large Pharma shopping list. No doubt these major players are already looking at post-COVID timescales. COVID gets SNG a foot in the door, but no doubt the larger, long-term interest will be COPD and then wider respiratory illness family, making SNG a potentially rich target into the longer-term. In the meantime however, RM quite rightly keeps his options open.
Despite his usual cheery face and upbeat confident responses, there was an underlying vision of a guy who was / is absolutely knackered. Can't begin to know how busy RM and team will be, but hopefully the new blood will start to make a difference. His 'back to back zoom calls' comment (as a contrast to ordinary 9-5 working days pre-Covid) gives some indication that he is probably working out of hours due to the global P3 with overseas partners and interested parties, etc. After all a couple of months extra wait is little enough given the efforts required to get this to market, so happy to wait ... and even added a few yesterday - rude not to. Batten down for a challenging winter for current/future patients, and lets see a brighter 2022 for the world and SNG.
I think this may tie in with Andy's point (ref SNG - who?) .. and also have reference to the new hirings (Comms etc) .. in that the webinar (having been addressed to analysts it seems) .. is to get the name and news further out into the world beyond just the small band of scientists, investors and believers so as to then have the awareness platform ready for the (imminent) BIG news of A2 & P3 results. Part of the big strategy.
Ref. thoughts around the high-profile hirings of late and how the near 'future' will play out (JV/BO/To, etc) ... I would think that RM et al will be 'playing a blinder' in terms of keeping all options open. What better way to play for gold, than to set up your own impressive top table to send a message to big Pharmas that we are ready & willing to captain and crew the SNG ship. It will be strategy (with knobs on) right now so it may be that cards remain even closer to chests, and thus leaving us to pontificate. So be it .... seen enough of RM to be sure of a good outcome, but don't doubt the pressure he & BoD will be under right now.
Apologies if already mentioned but couldn't see any reference to this ...
"Very proud to join the #NACAP team working to improve outcomes for patients with COPD."
Replying to: ..
"National Asthma and COPD Audit Programme
@NACAPaudit
ยท Sep 16
#NACAP are delighted to welcome @ProfWilko to the team as our new #COPD clinical lead!
We look forward to working with Professor Wilkinson to continue to improve COPD care and patient outcomes across the country.
@ProfHurst"
https://twitter.com/ProfWilko/status/1438848188396589056
Just when you think you have heard all the horrible stories another comes along and really does bring it home. How many must think that young and fit is enough ... it's lottery, and no-one knows till they get it how they will respond ... or not!
Does anyone else recall RM saying some months (and a couple of video presentations) ago, that they expected to have "interim results" on P3 ... suggesting some indication being reported ahead of 'final / formal' rests analysis ? If so, (and of course assuming at least similar positivity to that of P2) my thoughts were that this would be tactically / commercially sensible by raising the SP (before final results) and create a higher SP (springboard) position for main 'lift-off' and of course, ensure a higher projected BO/TO price.